FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Sebastian Raimundo

Research Profile

Chemicals & Drugs

Physiology

Genes & Molecular Sequences

Concepts & Ideas

Procedures

Genetic Testing

Occupations

Genetics, Population

Co-author Network

Publications

TOP 3
Kathrin Klein; Stephan Tatzel; Sebastian Raimundo; Tanja Saussele; Elisabeth Hustert; Juergen Pleiss; Michel Eichelbaum; Uli Zanger
A natural variant of the heme-binding signature (R441C) resulting in complete loss of function of CYP2D6.
Claudia Toscano; Sebastian Raimundo; Kathrin Klein; Michel Eichelbaum; Matthias Schwab; Uli Zanger
A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6.
Claudia Toscano; Kathrin Klein; Julia Blievernicht; Elke Schaeffeler; Tanja Saussele; Sebastian Raimundo; Michel Eichelbaum; Matthias Schwab; Uli Zanger
Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Sebastian Raimundo (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Kathrin Klein; Stephan Tatzel; Sebastian Raimundo; Tanja Saussele; Elisabeth Hustert; Juergen Pleiss; Michel Eichelbaum; Uli Zanger
A natural variant of the heme-binding signature (R441C) resulting in complete loss of function of CYP2D6.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(8):1247-50.
2006: Claudia Toscano; Sebastian Raimundo; Kathrin Klein; Michel Eichelbaum; Matthias Schwab; Uli Zanger
A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6.
Pharmacogenetics and genomics 2006;16(10):767-70.
2006: Claudia Toscano; Kathrin Klein; Julia Blievernicht; Elke Schaeffeler; Tanja Saussele; Sebastian Raimundo; Michel Eichelbaum; Matthias Schwab; Uli Zanger
Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.
Pharmacogenetics and genomics 2006;16(10):755-66.
2004: Sebastian Raimundo; Claudia Toscano; Kathrin Klein; Joachim Fischer; Ernst-Ulrich Griese; Michel Eichelbaum; Matthias Schwab; Uli Zanger
A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects.
Clinical pharmacology and therapeutics 2004;76(2):128-38.
2004: Uli Zanger; Sebastian Raimundo; Michel Eichelbaum
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Naunyn-Schmiedeberg's archives of pharmacology 2004;369(1):23-37.
2001: Uli Zanger; Joachim Fischer; Sebastian Raimundo; T Stüven; Bernd Evert; Matthias Schwab; Michel Eichelbaum
Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.
Pharmacogenetics 2001;11(7):573-85.
2000: Sebastian Raimundo; Joachim Fischer; Michel Eichelbaum; Ernst-Ulrich Griese; Matthias Schwab; Uli Zanger
Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6.
Pharmacogenetics 2000;10(7):577-81.